Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

On the Dangers of Cancer Exceptionalism in Pain Medicine.

Kennedy Institute of Ethics journal·2026
Same journal

Suck It Up and Stay on the Grind: Ethical Considerations Surrounding Trust, Chronic Pain, and the American Workplace.

Kennedy Institute of Ethics journal·2026
Same journal

<i>Morbus Mediterraneus</i>: A Cultural Alibi for an Unequal Pain Burden.

Kennedy Institute of Ethics journal·2026
Same journal

Beyond Words: A Philosophical Analysis of the Linguistic Refractoriness of Chronic Pain.

Kennedy Institute of Ethics journal·2026
Same journal

When "Good-Enough" Treatment Is Not Good Enough: Epistemic Injustice, Pain-Related Motivational Deficit, and Epistemic Deflection in the Treatment of Gynecological Pain.

Kennedy Institute of Ethics journal·2026
Same journal

The Silent Struggle: A Woman's Journey Through Pain.

Kennedy Institute of Ethics journal·2026

Related Experiment Videos

Pharmacogenomics, ethics, and public policy.

Karen Peterson-Iyer1

  • 1Markkula Center for Applied Ethics, Santa Clara University, CA, USA.

Kennedy Institute of Ethics Journal
|June 20, 2008
PubMed
Summary

Pharmacogenomics, studying genome's effect on drug response, offers benefits but raises ethical concerns. Public policy must ensure its development promotes individual and societal well-being.

Area of Science:

  • Genomics
  • Pharmacology
  • Bioethics

Background:

  • Pharmacogenomics, the study of how the human genome influences drug response, is increasingly driving pharmaceutical development in Western medicine.
  • While promising significant improvements in drug safety and efficacy, this field presents complex ethical challenges.

Purpose of the Study:

  • To critically examine the ethical implications of pharmacogenomics.
  • To propose public policy recommendations for responsible development and implementation of pharmacogenomics.

Main Methods:

  • Normative ethical analysis.
  • Review of existing literature on pharmacogenomics and bioethics.
  • Development of policy suggestions based on core ethical values.

Related Experiment Videos

Main Results:

  • Pharmacogenomics necessitates careful consideration of informed consent, confidentiality, justice, and equity.
  • Ethical frameworks must address both individual and societal impacts, nationally and globally.

Conclusions:

  • Approaching pharmacogenomics requires a balance of enthusiasm and critical evaluation.
  • Public policy informed by values of respect for persons, well-being, justice, and solidarity is crucial for beneficial pharmacogenomics development.